Pirfenidone: 8 agencies, 2012–2023
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: NICE (England) recorded restricted in TA504, while PBAC (Australia) recorded not recommended for “Idiopathic pulmonary fibrosis (IPF)”.
Assessment has run over 11.2 years, from 15 Mar 2012 at G-BA (Germany) to 21 May 2023 at NYE METODER (Norway).
PBAC (Australia) changed its position: not recommended in 2015, recommended by 2018, after a resubmission.
No assessment is on file from AWMSG (Wales) and CIPM (Spain), each among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for pirfenidone by the agencies that label one in English (NICE, PBAC and SMC).
4 of these 15 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
G-BA (Germany) was first to assess pirfenidone, on 15 Mar 2012; NYE METODER (Norway) did not open a file until 21 May 2023 — an unusually long tail of 11.2 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 8 years in total.
Restriction is doing real work here: 4 of 13 decisive outcomes narrowed pirfenidone to a subgroup rather than accepting or refusing it outright, at G-BA (Germany), NICE (England) and SMC (Scotland) among others.
3 of the 8 agencies here assessed pirfenidone more than once, PHARMAC (New Zealand) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for pirfenidone.
The full ledger for pirfenidone reads 8 recommended, 4 restricted, 1 other and 1 deferred, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 21 May 2023 | Til behandling av idiopatisk lungefibrose (ILF) hos voksne. | introduced | source |
| PHARMAC (New Zealand) | 5 Sep 2022 | Progressive fibrosing interstitial lung diseases | PTAC advice: Medium | source |
| NICE (England) | 6 Feb 2018 | NICE TA504 | recommended (optimised) | source |
| HAS (France) | 25 Oct 2017 | Listing (Transparency Committee) | SMR moderate · ASMR V | source |
| PBAC (Australia) | 2016 | Idiopathic Pulmonary Fibrosis | Re-submission to request an Authority Required listing for the treatment of idiopathic pul… | source |
10 further decisions for pirfenidone, across 5 agencies, are not shown here. They link to 7 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 15 decisions for pirfenidone from 8 agencies, 2012 to 2023. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.